Pharmaceuticals
CMI Inc. and Life Molecular Imaging Announce the Reimbursement of the Amyloid-PET Diagnostic Neuraceq® (florbetaben 18F) in Japan
First Reimbursed Amyloid PET Diagnostic Tool in Japan TOKYO and BERLIN, Nov. 23, 2023 /PRNewswire/ -- CMI Inc. and Life Molecular Imaging (LMI) are pleased to announce that the amyloid-PET diagnostic Neuraceq® (florbetaben18F injection) has been approved from the Ministry of Health, Labor, and ...
2023-11-23 01:00
3203
Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Type 2 Diabetes in Diabetes Care
ROCKVILLE, Md.and SUZHOU,China, Nov. 22, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ot...
2023-11-22 12:40
7616
XtalPi and EDDC Sign New Collaboration, Empowering Biomedical Innovation with Robotics and Large Language Models
SHENZHEN, China, Nov. 22, 2023 /PRNewswire/ -- Today, XtalPi announced that it has signed a Memorandum of Understanding (MOU) with the Experimental Drug Development Centre (EDDC),Singapore's national drug discovery and development platform hosted by A*STAR, for the expansion of their collaboratio...
2023-11-22 09:00
4073
Menarini Group Announces New Data on ORSERDU® (elacestrant) at the 2023 San Antonio Breast Cancer Symposium and on ELZONRIS® (tagraxofusp-erzs) at the 65th American Society of Hematology Annual Meeting and Exposition
- Data spans eleven presentations across both solid tumors and hematologic malignancies, providing added understanding of the potential benefit these therapies bring to patients - ORSERDU data reinforce its key role in the treatment of ER+, HER2- advanced or metastatic breast cancer (mBC) tumors...
2023-11-21 20:15
3524
Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day
* Clinical programs, including ATG-101 (PD-L1/4-1BB bispecific antibody), ATG-022 (Claudin 18.2 antibody-drug conjugate), and ATG-037 (oral CD73 inhibitor) have shown clinical responses in cancer patients with advanced diseases. * ATG-008 (dual mTORC1/2 inhibitor) continued showing strong cli...
2023-11-17 08:00
3065
TB Alliance Launches Five-Country Phase 2 Clinical Trial Evaluating Next-Generation TB Drug
Early results presented at the Union World Conference on Lung Health suggest promise of new compound to fight tuberculosis that will be tested as part of Phase 2 trial The first participant has been dosed in this partially double-blind study to evaluate the safety and efficacy of what has the po...
2023-11-16 20:20
2113
Henlius Reported Financial Results for the First Three Quarters of 2023: Total Revenue Exceeded RMB3.9 billion, Profitability Further Improved
SHANGHAI, Nov. 15, 2023 /PRNewswire/ -- Henlius（2696.HK）announced its financial results and business update for the first three quarters of 2023. As of September 30, 2023, Henlius generated a total revenue of RMB3.9278 billion, rising by 84.0% YoY, and a profit totaledRMB407.8 million, attributed ...
2023-11-15 20:16
4430
RemeGen to Present Telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in a Late-Breaking Abstract Oral Presentation Session at the American College of Rheumatology
YANTAI, China, Nov. 15, 2023 /PRNewswire/ -- RemeGen Co., Ltd.
2023-11-15 16:35
2911
"Read Medicine Labels" - How to Safely Use Green Chiretta Against COVID-19
Chula
2023-11-15 14:58
4768
Noble Capital Markets Initiates Coverage on YS Biopharma With Outperform Rating and US$5.25 Price Target
GAITHERSBURG, Md., Nov. 14, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...
2023-11-14 21:30
2055
Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023
Direct evidence that BRII-179-induced functional antibody responses can contribute to increased and sustained HBsAg loss rate New insight in utilizing BRII-179 to enriching patients with intrinsic humoral immune responses for higher HBsAg loss or HBV functional cure rates New data support ...
2023-11-14 06:40
3766
Telix Announces Proposed Acquisition of QSAM Biosciences and Its Lead Therapy Candidate, CycloSam®
MELBOURNE, Australia, Nov. 14, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has signed a conditional Term Sheet to acquire QSAM Biosciences, Inc. (QSAM) and its lead asset, CycloSam® (Samarium-153-DOTMP). QSAM is a United States (U.S.) based...
2023-11-14 06:33
2456
Rx-360 Releases Two New Publications in Support of the Pharmaceutical Industry and Patient Safety
PHILADELPHIA, Nov. 14, 2023 /PRNewswire/ -- Rx-360 is pleased to announce that the consortium membership led by key members of the Supplier Quality Working Group have released two new papers this week to help drive best practices in pharmaceutical supply chain integrity and patient safety. The t...
2023-11-14 03:00
3241
SCG Cell Therapy Announces Late-Breaking Clinical Data at AASLD Showing SCG101 Improved Tumor Reponses and Achieved Sustained Antiviral Activates in Patients with Advanced HBV-related Hepatocellular Carcinoma
SINGAPORE, Nov. 14, 2023 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, today announced late-breaking clinical data from its first-in-class autologous hepatitis B virus ...
2023-11-14 02:00
4615
Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)
Bylvay (odevixibat) is the first and only oral treatment available in Canada
for the treatment of pruritus due to this rare genetic condition
ZUG, Switzerland and PARIS, Nov. 13, 2023 /PRNewswire/ -- Today, Ipsen
2023-11-13 20:20
2339
TB Alliance Applauds Macleods' Launch of a Key Component of WHO-Recommended Drug-Resistant TB Treatment Regimen
Macleods becomes second pharmaceutical manufacturer to bring pretomanid supply to market and first since the World Health Organization issued updated DR-TB treatment guidelines NEW YORK, Nov. 13, 2023 /PRNewswire/ -- Indian pharmaceutical company Macleods has become the second manufacturer to la...
2023-11-13 18:31
2144
Fundiin partners with Pharmacity to launch BNPL at a thousand drugstores in Vietnam
Fundiin and Pharmacity have forged the first-ever Buy Now Pay Later (BNPL) partnership in the pharmacy retail sector, with Fundiin being the most popular BNPL provider inVietnam and Pharmacity emerging as the regional leading drugstore chain. HO CHI MINH CITY, Vietnam, Nov. 13, 2023 /PRNewswire/...
2023-11-13 14:58
4708
Ascletis Announces Poster Presentations at AASLD Annual Meeting 2023 Including a Late-Breaking Abstract of Interim Results from Phase IIb Expansion Cohort of ASC22 for Functional Cure of CHB
HANGZHOU and SHAOXING, China, Nov. 13, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces late-breaking abstract poster presentation of interim results from Phase IIb expansion cohort of ASC22 (Envafolimab) for functional cure of chronic hepatitis B (CHB), and abst...
2023-11-13 08:10
3986
Guardant Health launches Shield blood-based screening test for colorectal cancer in South Korea
SINGAPORE, Nov. 13, 2023 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that it has launched its blood-based colorectal cancer screening test, ShieldTM, in collaboration with Samsung Medical Center inSouth Korea. Colorectal cancer (CRC) is o...
2023-11-13 08:00
4781
Seegene Earns Improved ESG Rating from the Korea Institute of Corporate Governance and Sustainability
Company attributes B+ rating to progress related to its Human Rights Management Declaration, eco-friendly shipping box and the establishment of an internal ESG Committee SEOUL, South Korea, Nov. 10, 2023 /PRNewswire/ -- Seegene Inc. (KQ096530), a leading South Korean company providing a total so...
2023-11-10 20:00
4985
Week's Top Stories
Most Reposted
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
[Picked up by 312 media titles]
2026-10-13 10:00
Agoda and Emerging Travel Group Enter Strategic Partnership
[Picked up by 293 media titles]
2026-10-15 16:00Food & Hospitality Asia 2027 Redefining Excellence: The Premier Platform for Food & Beverage and Hospitality Innovation
[Picked up by 282 media titles]
2026-10-15 10:00SALMON SECURES $140 MILLION (PHP 8.8 BILLION) TO DOUBLE DOWN ON THE GROWTH OPPORTUNITY IN THE PHILIPPINES
[Picked up by 280 media titles]
2026-10-19 13:18
Leading Asian DMC Discova to Attend ITB Asia 2026
[Picked up by 280 media titles]
2026-10-15 12:59
Most Read
Sonilo Raises $11M to Build the AI-Native Audio Stack for Video
2026-10-15 00:00
23460
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
2026-10-13 10:00
22581
Agoda and Emerging Travel Group Enter Strategic Partnership
2026-10-15 16:00
12345